Prosecution Insights
Last updated: November 04, 2026
Application No. 18/057,454

CARDIAC MAPPING TO EVALUATE IMPACT OF INTERVENTIONS

Final Rejection §102
Filed
Nov 21, 2022
Priority
Jan 14, 2022 — provisional 63/299,591
Examiner
HULBERT, AMANDA K
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cardioinsight Technologies Inc.
OA Round
2 (Final)
85%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
660 granted / 779 resolved
+14.7% vs TC avg
Minimal +4% lift
Without
With
+4.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
24 currently pending
Career history
813
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
41.9%
+1.9% vs TC avg
§102
25.0%
-15.0% vs TC avg
§112
22.9%
-17.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 779 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Applicant’s amendment dated June 17,2026 is acknowledged. Currently claims 1-33 are are pending in this application with claims 1-16, 31, and 33 withdrawn from consideration. Response to Arguments Applicant’s arguments have been considered and are persuasive inasmuch as they apply to the amended claims. The rejections under 35 USC 101, 112, and 102 have been withdrawn. New rejections under 35 U.S.C. 102 have been included due to the amendments to the claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Regarding claim 17, Harlev discloses a system including non-transitory memory configured to store data and machine-readable instructions, the data including electrophysiological data representing cardiac electrophysiological signals for a plurality of locations across a cardiac surface over time (e.g. interface unit including storage medium 111); one or more processors adapted to access the memory and execute the instructions programmed to perform a method comprising: analyzing the electrophysiological data for multiple time intervals, wherein the multiple time intervals are defined by periods of consecutive heartbeats in cardiac cycles (e.g. therapy annotations that occur in real time as disclosed in [0073]); generating an electroanatomic map for the cardiac surface based on the electrophysiological data acquired over time that includes a first time interval of the multiple time intervals (e.g. therapy annotations that are generated and displayed in real time; [0073] using the interrogating energy as disclosed in step 643 of Figure 3); generating another electroanatomic map for the cardiac surface based on a second time interval of the multiple time intervals (e.g. therapy annotations that are generated and displayed in real time; [0073]); determining changes between the electroanatomic map for the first time interval and the other electroanatomic map for the other time interval, one of the first time interval or the second time interval occurring during or after application of a first intervention to temporarily perturb electrical properties of a region of interest on or within a patient's heart (e.g. therapy annotations that are generated and displayed in real time; [0073]- [0074]); and controlling a second intervention to permanently alter the electrical properties of the region of interest based on the determined changes (e.g. delivery of irreversible treatment therapy at step 647 of Figure 6). Regarding claim 18, Harlev additionally discloses an interventional device configured to deliver an energy corresponding to the first intervention and/or the second intervention to induce or inhibit conduction of electrical signals for the region of interest (e.g. medical device 104 as shown in Figure 3). Regarding claim 19, Harlev additionally discloses wherein the interventional device is configured to set a level of the energy based on control instructions provided by the one or more processors (e.g. varying the electrical energy level as disclosed in [0033]). Regarding claim 20, Harlev additionally discloses wherein the interventional device is configured to apply the first intervention directly to the region of interest (e.g. step 643 of Figure 6). Regarding claim 21, Harlev additionally discloses wherein the interventional device is configured to apply the first intervention including delivery of a non-lethal level of the energy agent to alter temporarily electrical properties of cardiac tissue in the region of interest for at least one cardiac cycle during the first time interval based on a first control instruction provided by the one or more processors (e.g. step 643 as shown in Figure 6). Regarding claim 22, Harlev additionally discloses wherein the one or more processors are further programmed to provide a second control instruction based on the electroanatomic maps or information derived from the electroanatomic maps indicating a desired change in a rhythm condition responsive to the first intervention, and the interventional device is configured to set a level of applied energy delivered by the interventional device during the second intervention based on the second control instruction (e.g. delivering irreversible therapy as disclosed in step 647 of Figure 6). Regarding claim 23, Harlev additionally discloses wherein the interventional device is a first interventional device, the system further comprising a second interventional device configured to apply the energy to permanently alter the electrical properties of the region of interest (e.g. medical device 124 and 125 as shown in Figure 1). Regarding claim 24, Harlev additionally discloses wherein the interventional device is configured to apply one of electrical stimulation (e.g. Abstract) Regarding claim 25, Harlev additionally discloses wherein the one or more processors are further programmed to generate guidance based on the determined changes indicating whether a desired effect is achieved responsive to the first intervention (e.g. detection of change in electrical activity as disclosed in step 644 of Figure 6). Regarding claim 26, Harlev additionally discloses wherein the one or more processors are further programmed to set a parameter to control the interventional device for the application of the second intervention based on the determined changes representing a positive therapeutic effect being achieved responsive to the first intervention (e.g. delivery of irreversible therapy at 647 when a change of electrical activity is detected at step 647 of Figure 6). Regarding claim 27, Harlev additionally discloses wherein the one or more processors are further programmed to display a recommendation to identify a next target region of interest for another application of the first intervention based on the determined changes representing a negative or lack of desired therapeutic effect being achieved responsive to the first intervention (e.g. new potential treatment site as disclosed in step 645 of Figure 6, as further disclosed in [0059] – [0060]). Regarding claim 28, Harlev additionally wherein prior to the application of the first intervention, the one or more processors are further programmed to generate the other electroanatomic map based on electrophysiological signals measured in the absence of any application of an intervention to perturb the electrical properties of the region of interest, and to identify the region of interest as a localized target identified on or within the patient's heart based on the other electroanatomic map (e.g. initial map of anatomical structure as shown in step 641). Regarding claim 29, Harlev additionally discloses wherein the region of interest includes a first region of interest and a second region of interest on or within the patient's heart, wherein prior to the application of the first intervention, the one or more processors are further programmed to: identify the second region of interest as a localized target identified on or within the patient's heart based on evaluating electrophysiological signals measured responsive to the application of the first intervention; and control the application of the second intervention to permanently alter the electrical properties of the second region of interest (e.g. step 645 of Figure 6 which finds other potential treatment sites. Regarding claim 32, Harlev additionally discloses wherein the other time interval occurs before the first time interval (e.g. as disclosed in Figure 6). Allowable Subject Matter Claim 30 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amanda K Hulbert whose telephone number is (571)270-1912. The examiner can normally be reached Monday - Friday 9:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Unsu Jung can be reached at 571-272-8506. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Amanda K Hulbert/Primary Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Nov 21, 2022
Application Filed
Mar 20, 2026
Non-Final Rejection mailed — §102
Jun 09, 2026
Applicant Interview (Telephonic)
Jun 09, 2026
Examiner Interview Summary
Jun 17, 2026
Response Filed
Oct 15, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779286
SYSTEM AND METHOD FOR RECOMMENDING PHYSICAL ROUTINE
3y 9m to grant Granted Nov 03, 2026
Patent 12778493
Visual Determination of Sleep States
2y 10m to grant Granted Nov 03, 2026
Patent 12779204
FLUID DELIVERY BASED INTRAVASCULAR REPERFUSION THERAPY DEVICES, SYSTEMS, AND METHODS
2y 7m to grant Granted Nov 03, 2026
Patent 12778791
Methods and Devices for Treating Sleep Apnea
1y 11m to grant Granted Nov 03, 2026
Patent 12773192
MECHANISM TO WAKE A BATTERY IN A SURGICAL DEVICE
3y 7m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
85%
Grant Probability
89%
With Interview (+4.2%)
3y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 779 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month